- Language: English
- Published: March 2014
- Region: Global
Common Cold Partnering 2009-2014
- Published: March 2014
- Region: Global
- 100 pages
The Common Cold Partnering 2009-2014 provides understanding and access to the common cold partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of common cold partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors common cold technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 30 links to online copies of actual common cold deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of common cold partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in common cold partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading common cold deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of common cold partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of common cold technologies and products.
Common Cold Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to common cold trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
Trends in common cold dealmaking in the biopharma industry since 2009
Access to summary headline, upfront, milestone and royalty data
The leading common cold deals by value since 2009
In Common Cold Partnering 2009-2014, the available deals are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. SHOW LESS READ MORE >
Chapter 1 – Introduction
Chapter 2 – Trends in common cold partnering
2.2. Common cold partnering over the years
2.3. Bigpharma common cold dealmaking activity
2.4. Common cold partnering by deal type
2.5. Common cold partnering industry sector
2.6. Common cold partnering by stage of development
2.7. Common cold partnering by technology type
2.8. Disclosed financial deal terms for common cold partnering
2.8.1 Common cold headline values
2.8.2 Common cold upfront payments
2.8.3 Common cold milestone payments
2.8.4 Common cold royalty rates
Chapter 3 – Leading common cold deals
3.2. Top common cold deals by value
3.3. Top common cold deals involving bigpharma
Chapter 4 – Dealmaking directory
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type
Diagnostic - companion
In vitro models
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendix 1 – Deal type definitions
About Wildwood Ventures
Recent titles from CurrentPartnering
Order Form – Reports
Table of figures
Figure 1: Common cold partnering since 2009
Figure 2: Bigpharma – top 50 – common cold deals 2009 to 2011
Figure 3: Bigpharma common cold deal frequency – 2009 to 2011
Figure 4: Common cold partnering by deal type since 2009
Figure 5: Common cold partnering by industry sector since 2009
Figure 6: Common cold partnering by stage of development since 2009
Figure 7: Common cold partnering by technology type since 2009
Figure 8: Common cold deals with a headline value
Figure 9: Common cold deals with upfront payment values
Figure 10: Common cold deals with milestone payments
Figure 11: Common cold deals with royalty rates, %
Figure 12: Top common cold deals by value since 2009
Figure 13: Top common cold deals signed by bigpharma value since 2009
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions
The Common Cold Partnering 2007-2012 report provides understanding and access to the common cold partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in common cold partnering deals
Top common cold deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type
On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.
The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co